Phelps Brand Welcomes World Champion Swimmer Penny Oleksiak as Global Brand Ambassador
8.10.2020 18:00:00 EEST | Business Wire | Press release
Phelps Brand today announced Canada’s youngest World Champion swimmer Penny Oleksiak is joining the team as an official global ambassador. As part of the Phelps Team, Oleksiak will train and compete utilizing the industry-leading range of products from training equipment to performance swim suits, including the FINA-approved Matrix Technical suit, which is available now to consumers worldwide at www.michaelphelps.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005297/en/
Michael Phelps welcomes World Champion swimmer Penny Oleksiak to the Phelps Brand. Photo courtesy of Phelps Brand.
Oleksiak, a World Champion swimmer and Olympic-record holder, has been tapped as the face of the Matrix campaign, the Phelps Brand’s first new product launch in 2020. As part of the Phelps Team, Oleksiak (CAN) will help advance the brand globally alongside the growing roster of elite athletes including World Champion and American-record holder Chase Kalisz (USA), two-time Olympian Georgia Davies (UK), French-record holder David Aubry (FRA) and Olympian Luca Pizzini (IT).
“I’m a big fan of Penny and what she’s been able to accomplish in the pool. I’m thrilled she is joining the Phelps Team as the first female global ambassador,” said Phelps. “Penny is a tremendous athlete who shares my passion for the sport and has already provided a lot of great insights for the Phelps Brand. Her personality, talent and confidence are huge assets for the entire swimming community.”
A four-time Olympic medalist and six-time World Championship medalist, Oleksiak is a force on Team Canada. As Canada’s youngest Olympic gold medalist, she holds the nation’s record for most Olympic medals at a single summer games. In her short career she has become known for her exciting come from behind victories, winning four Olympic and six World medals; and currently holds the Olympic Record for the 100 Freestyle.
“I am so excited to be part of the Phelps Team,” said Oleksiak. “I have looked up to Michael my entire career and now have the chance to learn from and work alongside him to bring an incredible experience and line of products to the swimming community. It really is a dream come true for me.”
The Phelps Brand, which originally launched as MP Brand in 2015, continues to develop technologically advanced racing and training suits for competitive swimmers under the direction of Michael Phelps and Hall of Fame coach Bob Bowman.
The first product to launch under the Phelps Brand is the Matrix Tech Suit, a top-of-the-line FINA-approved competitive tech suit created with propriety Exo-Core technology. The Matrix features both adaptive compression material to reduce muscle vibration and drag while ensuring maximum flexibility and freedom of movement. In addition, the Matrix includes a sustaining tape system for improved body position by utilizing front and back axis tape and cross-coordinating to improve length and position.
“Penny is a tremendous athlete and her unique experiences and insights will play a key role in helping inform the competitive swim product innovation in the Phelps Brand today,” said Andrew Gritzbaugh, General Manager of North America for Aqua Lung, the parent company of Phelps Brand and Aqua Sphere. “We’re very excited to welcome her to the team and look forward to supporting her in her future endeavors.”
To purchase Phelps Brand products go to www.michaelphelps.com.
About PHELPS BRAND
The Phelps Brand offers best-in-class, innovative swim products that are inclusive and accessible to a broad range of swimmers across the competitive swimming lifecycle. Combining Aqua Sphere’s global product design expertise and distribution with Michael Phelps’ and Coach Bob Bowman’s experiences at the highest levels of swim performance, the Phelps Brand features technical swim products leveraging proprietary technologies and performance enhancing designs. For more information, visit www.michaelphelps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005297/en/
Contact information
Lindsay Goodson
lgoodson@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom